display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced RCC (mRCC) - 1st line (L1)
metastatic/advanced RCC (mRCC) - 1st line (L1)mRCC - L1 - PDL1 negativemRCC - L1 - PDL1 positive
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone IMmotion-150 ... IMmotion-150 ...
atezolizumab plus bevacizumab IMmotion-150 ... IMmotion-151 ... IMmotion-151 ... IMmotion-150 ... IMmotion-151 ...
avelumab based treatment
avelumab plus axitinib JAVELIN Renal 101 ... JAVELIN Renal 101...
nivolumab based treatment
nivolumab plus cabozantinib CheckMate 9ER
pembrolizumab based treatment
pembrolizumab plus axitinib KEYNOTE-426
pembrolizumab plus lenvatinib KEYNOTE-581/CLEAR ...
Immune checkpoint association
nivolumab plus ipilimumab CheckMate 214 ... CheckMate 214 ... CheckMate 214 ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons